NCT04269460

Brief Summary

The aim of this work to compare the analgesic efficacy of preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block in pediatric patients undergoing pyeloplasty surgeries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2020

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

February 11, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 13, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2021

Completed
Last Updated

March 16, 2021

Status Verified

March 1, 2021

Enrollment Period

1.1 years

First QC Date

February 11, 2020

Last Update Submit

March 14, 2021

Conditions

Keywords

ultrasoundquadratus lumborumsubcostal TAPpediatricspyeloplasty

Outcome Measures

Primary Outcomes (1)

  • Post-operative pain score by The Face, Legs, Activity, Cry, Consolability scale (FLACC) scale at 12 hours

    The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.

    24 hours

Secondary Outcomes (3)

  • • Time to first request of postoperative rescue analgesics

    24 hours

  • • Total consumption of opioids

    24 hours

  • • Block performance time

    24 hours

Study Arms (2)

subcostal transversus abdominis plane block (sTAP)

ACTIVE COMPARATOR

patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.

Drug: Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]

quadratus lumborum block (QLB)

ACTIVE COMPARATOR

patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.

Drug: Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]

Interventions

preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.

quadratus lumborum block (QLB)subcostal transversus abdominis plane block (sTAP)

Eligibility Criteria

Age3 Months - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • American Society of Anesthesia (ASA) physical status I-II.
  • Age: 3 months to 5 years.
  • Undergoing pyeloplasty surgeries.

You may not qualify if:

  • Refusal of parents.
  • Patients with coagulation disorders (INR \> 1.5 and/or platelets \< 100 000).
  • History of allergic reactions to local anesthetics.
  • Rash or signs of infection at the injection site.
  • Emergency surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kasralainy

Cairo, 11559, Egypt

Location

MeSH Terms

Conditions

Agnosia

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia, Cairo university hospitals

Study Record Dates

First Submitted

February 11, 2020

First Posted

February 13, 2020

Study Start

February 1, 2020

Primary Completion

March 1, 2021

Study Completion

March 1, 2021

Last Updated

March 16, 2021

Record last verified: 2021-03

Locations